HER2 exon 20 insertion

Where the papers sit

11 papers from the last 6 months study HER2 exon 20 insertion directly · updated from PubMed 3 Oct 2026

• Breast Cancer Monitoring

  Circulating tumor cells and extracellular vesicles are being explored to track TROP2- and HER2-directed treatment in breast cancer. Fluorescence-guided delineation of minimal residual disease adds a route toward more precise detection after therapy. The recurring focus is translational measurement of tumor burden, treatment response, and residual disease rather than a single therapeutic mechanism. Evidence remains exploratory, with no clear consensus on the best monitoring platform.

  4 papers · 36.4%

• Anti-HER2 Antibody Therapeutics

  Trastuzumab-based therapy is being extended through pertuzumab pairing, immune checkpoint blockade, and enzymatic remodeling of tumor-cell surfaces. Engineered bispecific and single-domain binders point toward more adaptable antibody formats with improved target engagement. Evidence spans gastroesophageal adenocarcinoma treatment, pancreatic-cell activity, and protein-design studies, making efficacy context-dependent. The shared aim is to strengthen antibody binding or antitumor activity rather than define exon 20-specific biology.

  3 papers · 27.3%

• Others — HER2 Translational Research

  HER2-related work here has no single clinical trajectory. The topics range from zongertinib pharmacokinetics and resource use in HER2-negative gastroesophageal cancer to optogenetic antigen recognition and HER2-deficiency developmental phenotypes. These studies address drug exposure, treatment utilization, receptor control, and developmental biology rather than one shared question. No recurring therapeutic strategy or endpoint unifies the cluster.

  4 papers · 36.4%